Wells Fargo’s SELLAS Life Sciences SLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$955K Sell
225,707
-73,598
-25% -$329K ﹤0.01% 3758
2025
Q4
$1.13M Buy
299,305
+223,438
+295% +$434K ﹤0.01% 3875
2025
Q3
$122K Buy
75,867
+22,052
+41% +$39.3K ﹤0.01% 5216
2025
Q2
$118K Buy
53,815
+50,812
+1,692% +$78K ﹤0.01% 5100
2025
Q1
$3.24K Buy
+3,003
New +$3.56K ﹤0.01% 6093
2024
Q2
Sell
-301
Closed -$304 7411
2024
Q1
$304 Sell
301
-16,056
-98% -$13.5K ﹤0.01% 6398
2023
Q4
$17.3K Buy
16,357
+40
+0.2% +$43 ﹤0.01% 5687
2023
Q3
$26.8K Buy
16,317
+3
+0% +$5 ﹤0.01% 5478
2023
Q2
$25.6K Buy
16,314
+172
+1% +$276 ﹤0.01% 5664
2023
Q1
$23.1K Buy
16,142
+2
+0% +$5 ﹤0.01% 5577
2022
Q4
$38.1K Buy
16,140
+5,004
+45% +$14K ﹤0.01% 4989
2022
Q3
$22K Sell
11,136
-1
-0% -$3 ﹤0.01% 5352
2022
Q2
$25K Buy
11,137
+5,039
+83% +$14.8K ﹤0.01% 5351
2022
Q1
$41K Sell
6,098
-512
-8% -$2.99K ﹤0.01% 5750
2021
Q4
$37K Buy
6,610
+2,500
+61% +$18.9K ﹤0.01% 6108
2021
Q3
$37K Sell
4,110
-2,744
-40% -$25.5K ﹤0.01% 5737
2021
Q2
$76K Buy
6,854
+19
+0.3% +$185 ﹤0.01% 5399
2021
Q1
$58K Buy
6,835
+6,780
+12,327% +$55.5K ﹤0.01% 5748
2020
Q4
$0 Hold
55
﹤0.01% 6963
2020
Q3
$0 Buy
55
+10
+22% +$27 ﹤0.01% 6839
2020
Q2
$0 Buy
45
+7
+18% +$19 ﹤0.01% 6761
2020
Q1
$0 Buy
+38
New +$98 ﹤0.01% 6730
2019
Q4
Sell
-1
Closed 6695
2019
Q3
$0 Hold
1
﹤0.01% 6677
2019
Q2
$0 Sell
1
-12
-92% -$426 ﹤0.01% 6591
2019
Q1
$1K Sell
13
-3
-19% -$209 ﹤0.01% 5961
2018
Q4
$1K Buy
16
+1
+7% +$77 ﹤0.01% 6301
2018
Q3
$1K Buy
15
+3
+25% +$207 ﹤0.01% 6316
2018
Q2
$2K Hold
12
﹤0.01% 6195
2018
Q1
$2K Sell
12
-1
-8% -$285 ﹤0.01% 6209
2017
Q4
$5K Hold
13
﹤0.01% 6058
2017
Q3
$7K Sell
13
-1
-7% -$660 ﹤0.01% 5954
2017
Q2
$11K Sell
14
-2
-13% -$1.74K ﹤0.01% 5762
2017
Q1
$14K Buy
16
+5
+45% +$8.28K ﹤0.01% 5790
2016
Q4
$32K Buy
+11
New +$64K ﹤0.01% 5509

Other funds holding SLS

Wells Fargo's SLS Position: Q1 2026 in Review

Wells Fargo reduced its SELLAS Life Sciences (SLS) stake by 25% in Q1 2026, selling an estimated $329K and leaving 225,707 shares worth $955K. The position accounts for ﹤0.01% of the portfolio, ranked #3758.

Wells Fargo first reported a position in SLS in Q4 2016 and has held it in 34 quarters since. The position peaked at $1.13M in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Wells Fargo held 225,707 shares of SELLAS Life Sciences worth $955K as of Q1 2026.
  • Wells Fargo sold 73,598 SELLAS Life Sciences shares in Q1 2026, an estimated $329K.
  • SELLAS Life Sciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3758 holding.
  • Wells Fargo first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 34 quarters since.
  • Wells Fargo's SELLAS Life Sciences position peaked at $1.13M in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.